Fusion Antibodies plc provided earnings guidance for the first half of fiscal year 2024. For the period, the company expects revenue to be behind current market expectations, at not less than £541,000.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.845 GBX | +4.20% | +11.45% | -9.53% |
Apr. 30 | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | AN |
Apr. 15 | Fusion Antibodies inks commercial contract for OptiPhage library | AN |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.53% | 4.48M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.38% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- FAB Stock
- News Fusion Antibodies plc
- Fusion Antibodies plc Provides Earnings Guidance for the First Half of Fiscal Year 2024